Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea
NCT ID: NCT01372956
Last Updated: 2011-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4950 participants
OBSERVATIONAL
2011-08-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dyslipidemia
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.
Exclusion Criteria
* Patient who participated in other clinical study with study drug within 90 days.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeong Ui Park
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Jong sung Kim
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Sung woo Park
Role: PRINCIPAL_INVESTIGATOR
Kangbuk Samsung Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Busan, Busan, South Korea
Research Site
Cheonan, Chungcheongnam-do, South Korea
Research Site
Tae, Chungcheongnam-do, South Korea
Research Site
Chuncheon, Gangwon-do, South Korea
Research Site
Gwangju, Gwangju, South Korea
Research Site
Anyang-si, Gyeonggi-do, South Korea
Research Site
Bucheon-si, Gyeonggi-do, South Korea
Research Site
Bundang, Gyeonggi-do, South Korea
Research Site
Goyang-si, Gyeonggi-do, South Korea
Research Site
Guri-si, Gyeonggi-do, South Korea
Research Site
Uijeongbu-si, Gyeonggi-do, South Korea
Research Site
Incheon, Incheon, South Korea
Research Site
Gwangju, Jeollabuk-do, South Korea
Research Site
Iksan, Jeollabuk-do, South Korea
Research Site
Daegu, Kyeongsangbuk-do, South Korea
Research Site
Deagu, Kyeongsangbuk-do, South Korea
Research Site
Busan, Kyeongsangnam-do, South Korea
Research Site
Changwon, Kyeongsangnam-do, South Korea
Research Site
Cheongju-si, North Chungcheong, South Korea
Research Site
Seoul, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CKR-XXX-2011/1
Identifier Type: -
Identifier Source: org_study_id